Test Price
2,800 AED✅ Home Collection Available
SDHD Gene Sequencing for Cowden Syndrome Type 3 Susceptibility | NGS Genetic Test in Dubai
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance by a DHA-licensed Consultant Medical Genetics for result interpretation.
- Insurance: Direct Billing Verification available via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced Next Generation Sequencing (NGS) test provides comprehensive analysis of the SDHD gene coding and splice regions. It is specifically designed to detect pathogenic mutations associated with Cowden syndrome type 3, a hereditary condition that significantly elevates the risk for breast, thyroid, and endometrial malignancies. The result enables evidence-based cancer surveillance, risk-reducing surgical planning, and cascade testing for at-risk family members.
| Feature | Our Test (DNA Labs UAE) | Closest Alternative (Single-Site Panel) |
|---|---|---|
| Diagnostic Sensitivity | 99.9% (full gene NGS coverage) | ~92% (targeted hotspots only) |
| Methodology | NGS – Full SDHD coding & splice regions | Sanger sequencing of selected exons |
| Turnaround Time | 21 to 28 Days (3 to 4 Weeks) | 5–6 Weeks (often delayed) |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I emphasize that genetic testing for Cowden syndrome type 3 provides a crucial window into hereditary cancer risk. However, the results must be correlated with clinical findings, family pedigree, and followed by expert genetic counselling. This test can guide surveillance and preventive strategies when applied appropriately.”
— Dr. Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory & Medication Safety
Do not discontinue or alter any prescribed medication or oncology surveillance regimen based solely on genetic test results without consulting your treating physician. This test is a risk assessment tool and does not replace standard clinical examinations or oncologic care protocols.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Active systemic infection at the time of blood draw; inability to provide valid informed consent (legal guardian consent required for minors as per UAE Federal Law); severe coagulopathy or anticoagulation therapy that complicates standard venipuncture.
- Emergency Red Flags: If you experience acute chest pain, shortness of breath, sudden high fever, or any signs of anaphylaxis prior to sample collection, seek emergency medical care immediately and postpone the test.
Patient FAQ & Clinical Guidance
1. What is the purpose of SDHD gene testing for Cowden syndrome type 3?
This test identifies inherited mutations in the SDHD gene associated with Cowden syndrome type 3, which significantly increases the risk for breast, thyroid, and endometrial cancers. The NGS-based analysis provides comprehensive coverage to guide personalized cancer surveillance and risk management strategies for patients and their families.
2. What type of sample is required and how is it collected?
A standard peripheral whole blood sample is sufficient for this analysis. Our certified phlebotomists conduct home collections using a temperature-controlled cold-chain logistics framework from 8 AM to 11 PM daily. Alternatively, patients may provide their sample directly at our DHA-licensed facility in Dubai Healthcare City.
3. What is the cost of the test and does insurance cover it?
The total fee is 2,800 AED. This covers the complete NGS analysis, clinical interpretation, and a scheduled post-test telephonic consultation with a DHA-licensed genetics specialist. Direct billing verification and insurance coverage eligibility can be performed promptly through our WhatsApp service at +971 54 548 8731.
4. How long does it take to receive results?
The standard turnaround time is 21 to 28 days (3 to 4 weeks) from the date the sample is logged into our ISO 9001:2015 accredited laboratory. A comprehensive clinical report will be provided upon completion.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates in strict compliance with the UAE's legislative framework for health data and genetic information. Our processes adhere to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety protocols are aligned with Federal Decree-Law No. 4 of 2016 on Medical Liability. Our DHA Facility License Number is 1143, and our laboratory is located at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | SDHD Gene Sequencing (Cowden Syndrome Type 3 Susceptibility) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21–28 Days (3 to 4 Weeks) |
| Sample Type / Matrix | Whole Blood (Peripheral) |
| Methodology Used | Next Generation Sequencing (NGS) – Full Coding & Splice Regions |
| ICD-10-CM Code | Q85.8 (Cowden Syndrome) |
| LOINC Code | 65607-2 (SDHD Full Gene Sequencing) |
| DHA Facility License & Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians